Prime Minister Narendra Modi may have shown commitment to quickly conclude the discussion around Regional Comprehensive Economic Partnership, or RCEP, but this partnership agreement can derail his yet to take off Make in India programme.

The notice from the Drug Controller General of India follows raids by drug inspectors at various locations across the country on October 5-6.

The decision was taken after drug makers filed a petition, saying that these drugs were being manufactured since 1988. They cited the SC's earlier relief to 15 manufacturers on the bases of the similar grounds, saying that they should also be exempted from the ban.

The FDC medicines are two or more drugs contained in a single dosage form. The health ministry says it took the decision to ban these drugs after the Drugs Technical Advisory Board suggested these drugs might pose a risk to human beings.

This declaration will set the tone of the policy direction in which global community will move to tackle the menace of TB.

In a concept note released on June 8, NITI Aayog said that the move is in line with the government plan to achieve the overall goal of affordable healthcare for all by making all critical and lifesaving medical devices available at affordable prices.

Indian pharma is on edge with an expected pharma pricing overhaul, but nothing is known yet on the shape of things to come.

The inspection team, which inspected the facilities between February 2-23, gave a 'voluntary action indicated' (VAI) remark to Sun's Halol plant in Gujarat.

The Nipah virus (NiV) induced fever causes high fatality rate (40-80 percent) and spreads mainly through bats, pigs and other animals.

Even as US President Donald Trump wants United States Trade Representative (USTR) to step pressure on the country's trade partners to provide pricing freedom for US based medical device companies, local industry lobby group Association of Indian Manufacturers of Medical Devices (AIMED) has urged India to reduce reliance on imported medical devices.

Chinese Ambassador to India Luo Zhaohui's recent tweet on his country's decision to remove import duties on 28 medicines, including all cancer drugs, has created flutters in India.

India's drug pricing authority is also pushing to bring three more devices used while treating heart ailments under the ambit of price controls as they are sometimes more expensive than the stent itself.